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Liposomehe cationic lipid DOTAP and cholesterol is examined in high cholesterol for-
mulations by differential scanning calorimetry (DSC). Preparation of liposomes above 66 mol% cholesterol
results in formulations that exhibit a calorimetric transition for anhydrous cholesterol at 38–40 °C. The
enthalpy of this transition progressively increases at higher cholesterol contents, and is not detected below
66 mol% cholesterol. Furthermore, the enthalpy changes indicate that the composition of the non-domain
forming portion containing DOTAP saturated with cholesterol is relatively constant above 66 mol%
cholesterol. Greater transfection efﬁciency in the presence of 50% serum is observed at the formulations
with high cholesterol contents where anhydrous cholesterol domains are detected by DSC. Although
formulations possessing higher cholesterol exhibited a greater resistance to serum-induced aggregation,
maintenance of small particle size does not appear to be responsible for the enhanced transfection
efﬁciency. Additional studies quantifying albumin binding suggest that cholesterol domains in the lipid/
DNA complex do not bind protein, and this may enable these moieties to enhance transfection by facilitating
membrane fusion.
© 2008 Elsevier B.V. All rights reserved.1. Introduction
Cationic liposomes have been used extensively for in vitro and
in vivo gene delivery in the past decade. However, systemic delivery of
cationic lipid/DNA complexes (lipoplexes) is hindered by the interac-
tion between serum and lipoplexes, which can dramatically lower the
transfection efﬁciency [1–4]. Serum has been reported to exert its
inhibitory effect by binding serum proteins to cationic lipid/DNA
complexes, which leads to structural reorganization, aggregation and/
or dissociation of the complexes [3,5–7]. Thus, there is an intense effort
to develop lipoplexes that efﬁciently transfer genes in the presence of
serum. Among the pursuits toward this goal, the predominant strategy
is to utilize PEGylated components to sterically shield the delivery
vehicles from blood components [8–10]. However, PEGylation is
known to interfere with processes involved in intracellular delivery
and render vectors more susceptible to agitation-induced damage
during processing [10–13]. As a potential alternative to PEGylation,
experiments with vectors incorporating high levels of cholesterol
suggest that the resistance of vectors to serum-induced aggregation is
enhanced at progressively higher cholesterol contents [5,7,14,15].
Considering the drawbacks of PEGylation, it seems prudent to further
investigate lipid systems incorporating high levels of cholesterol.
Previous studies on the behavior of cholesterol in bilayers have
clearly demonstrated that cholesterol preferentially interacts with1 303 315 6281.
l rights reserved.diacyl lipids, e.g., phosphatidylcholine and phosphatidylethanolamine
[16]. This behavior has also been shown to be relevant to non-viral
vectors in that cholesterol's interactionwith diacyl cationic lipids (e.g.,
DOTAP) is similar to that with other diacyl lipids [17]. Recently, Epand
et al. [18] studied the properties of mixtures of cholesterol with
dioleoylphosphatidycholine (DOPC) and with several other phospho-
lipids as a function of cholesterol mole fraction and temperature. Their
results showed that mixtures of DOPCwith a cholesterol mole fraction
of 0.4 or greater displayed polymorphic behavior. Lipid polymorphism
is accompanied by the phase separation of cholesterol “crystallites” in
the anhydrous form and/or the monohydrate form.
In the present study, we examined the interaction between the
cationic lipid DOTAP and cholesterol. We report that liposome
preparation at high cholesterol content (≥66 mol%) results in the
formation of a cholesterol domain within the delivery vehicle. The
presence of the domain is detectable by differential scanning
calorimetry (DSC), and is consistent with the solubility limit of
cholesterol in diacyl lipids. Interestingly, our experiments show that
cholesterol in excess of its solubility remains associated with the
lipid component as a domain, consistent with previous reports [19].
Furthermore, the domain formation is not altered by DNA binding to
the DOTAP/cholesterol liposomes at different charge ratios. Lipoplexes
possessing cholesterol domains exhibit higher transfection efﬁciency
in 50% serum, and the previously-reported ability of high cholesterol
lipoplexes to resist serum-induced aggregation does not appear to be
responsible for these observations [7]. Additional experiments dem-
onstrate that albumin does not bind to the cholesterol domains, and
we suggest that these structures may present a favorable surface for
Fig. 2. Calculated transition enthalpy of DOTAP/cholesterol samples (0.25 mMDOTAP in
ddH2O) from DSC heating scan. DOTAP/cholesterol samples with 60, 65, 66, 67, 68, 70
and 80 mol% cholesterol were heated by DSC at a scan rate of 90 °C/hr. The area under
the anhydrous cholesterol transition (38–40 °C) was calculated to determine the
enthalpy change of the transition. Data represent mean±one standard deviation of
triplicate preparations.
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proteins.
2. Materials and methods
2.1. Materials
Luciferase plasmid DNA (5.9 kb) was generously provided by Valentis Inc.
(Burlingame, CA).N-(1-(2, 3-dioleoyloxy) propyl)-N,N,N-trimethylammonium chloride
(DOTAP) was purchased from Avanti Polar Lipids (Alabaster, AL). Synthetic cholesterol
and bovine serum albumin were purchased from Sigma-Aldrich (St. Louis, MO). The
luciferase assay kit was obtained from Promega (Madison,WI). Fetal bovine serum (FBS)
was purchased from Mediatech Inc. (Manassas, VA) and was ﬁltered with 0.22-µm low
protein binding cellulose acetate ﬁlter from Fisher Scientiﬁc (Pittsburgh, PA) before use.
All chemicals were of reagent grade or higher quality.
2.2. Liposome and lipoplex preparation
DOTAP combined with cholesterol at different mole percents (60%–80%) was mixed
in chloroform. The lipid mixture was dried under a stream of nitrogen gas and placed
under vacuum (100 mTorr) for 2 h to remove residual chloroform, and dried lipids
were subsequently resuspended in autoclaved, distilled water and sonicated. Cationic
liposomes were prepared the day before the experiment, stored overnight at 4 °C, and
sonicated immediately before use as previously described [7]. Lipoplexeswere prepared
by mixing equal volumes of DNA (40 μg/ml) and liposomes (0.5 mM), and incubation at
room temperature for 15 min.
2.3. Differential scanning calorimetry (DSC)
Liposomes with different cholesterol contents were prepared for DSC measure-
ments using a Microcal VP-DSC (Microcal Inc., Northampton, MA). The heating scanwas
from 10–90 °C at the rate of 90 °C/h. DSC curves were analyzed by using the ﬁtting
program (DSC Origin 7.0) provided by Microcal Inc.
2.4. Dynamic light scattering and zeta potential analysis
Lipoplexes at charge ratio of 4:1 were diluted to a ﬁnal volume of 500 μl with 10mM
HEPES pH 7.4. Diluted samples were transferred to a cuvette for dynamic light scattering
analysis on a Nicomp 380 Zeta Potential/Particle Sizer (Particle Sizing Systems, Santa
Barbara, CA). Channel width was set automatically based on the rate of ﬂuctuation of
scattered light intensity and triplicate preparationsweremeasured at room temperature
for each formulation. Volume-weighted Gaussian size distribution was ﬁt to the
autocorrelation functions and particle size values were obtained as previously described
[20]. Samples were then subjected to an electric ﬁeld in a Nicomp 380 Zeta Potential/
Particle Sizer for zeta potential determination. For size determination of lipoplexes
exposed to serum, lipoplexes were incubated in fetal bovine serum (50% v/v) at 37 °C
(ﬁnal DNA concentration=10 μg/ml). After 30 min, 50 µl of this sample was diluted in
500 µl water for size determination. Control samples of diluted serum lacking lipoplexes
did not exhibit a measurable particle size.
2.5. In vitro transfection assay
KB cells (ATCC #CCL-17™) were obtained from American Type Culture Collection
(Rockville, MD). Cells were incubated at 37 °C in a humidiﬁed atmosphere containing 5%
CO2. Cells were maintained in RPMI 1640 medium supplemented with 10% fetal bovine
serum (FBS), 50 U/ml penicillin G and 50 μg/ml streptomycin sulfate. For in vitro
transfection, cultures were freshly seeded at 3×105 cells/well in 12-well plates 24 h
before transfection. Lipoplexes (40 μl) containing 0.8 μg DNA were incubated at room
temperature for 15 min and then transferred into wells containing freshly washed cells
in 50% FBSmedium. The cells were incubatedwith lipoplexes for 4 h before themediumFig. 1. DSC heating scan of liposomes formulated with DOTAP and 60, 70 and 80 mol%
cholesterol as indicated in the graph, scan rate=90 °C/h, 0.25 mM DOTAP in deionized,
distilled water (ddH2O).was replaced with the medium containing 10% FBS. Forty hours after transfection, the
culture medium was discarded, and the cells were washed with phosphate buffered
saline (PBS) and then lysed with 200 μl of lysis buffer (Promega). Twenty microliters of
cell lysis solution was used to assay for luciferase expression via a luciferase assay kit
(Promega), according to the manufacturer's protocol. The signal was quantiﬁed using a
Monolight 2010 Luminometer (BD Biosciences, San Jose, CA). Protein contents were
determined with a Bio-Rad protein assay kit (Hercules, CA) according to the manu-
facturer's instructions. The absorbance was measured at 550 nm using a THERMOmax
microplate reader (Molecular Devices, Sunnyvale, CA).
2.6. Serum protein binding
Lipoplexes at charge ratio of 4:1 were prepared as mentioned previously (ﬁnal
concentration of DOTAP=0.25 mM). One hundred microliters of BSA (0.4 mg/ml) was
mixed with lipoplexes at equal volume and incubated at room temperature for 30 min.
After incubation, samples were centrifuged at 13,000 g for 1 h. Protein concentration of
the supernatant of each sample, i.e. the unbound protein content, was determined with
a Bio-Rad protein assay kit (Hercules, CA) according to the manufacturer's instructions.
Protein content bound to lipoplexes was then calculated by subtracting the unbound
portion from the total protein used, and normalized to the amount of DOTAP that
remains un-neutralized by DNA.
3. Results
3.1. DSC measurements
Previous studies have documented that mixtures of phospholipids
and cholesterol show a phase transition of cholesterol “crystallites”
above a particular mole percent of cholesterol [18]. There are two
kinds of cholesterol crystallites that can form: anhydrous cholesterol
and cholesterol monohydrate [21]. Anhydrous cholesterol can be
detected by the presence of the thermotropic transition between two
polymorphic forms that occurs at approximately 38 °C on heating [22].
In contrast, cholesterol monohydrate generally undergoes dehydra-
tion at about 80 °C that is very slowly reversible, requiringmany hours
for the process [21]. To determine whether either of these forms ofFig. 3. DSC heating scan of lipoplexes prepared with 0.5 mM DOTAP/cholesterol and
40 μg/ml plasmid DNA (charge ratio 4:1). Complexes were incubated at room tem-
perature for 15 min before the DSC scan. The scan rate was 90 °C/hr.
Fig. 4. Calculated transition enthalpy of lipoplexes prepared with 0.5 mM DOTAP/
cholesterol and 40 μg/ml plasmid DNA at charge ratio of 4:1 ( ), 3:1 ( ) and 2:1 (■).
Liposome only (□) is also shown as a control. Data represent mean+one standard
deviation of three replicates.
Fig. 5. In vitro transfection of DOTAP/cholesterol lipoplexes prepared with 60, 70, or 80
mole percent cholesterol. The data represent themean+one standard deviation of three
replicates.
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and cholesterol, samples composed of varying mole percent choles-
terol were analyzed with DSC. Our results indicate that liposomes
prepared with cholesterol contents of 70 and 80 mol% exhibit a
polymorphic transition consistent with anhydrous cholesterol at 38–
40 °C, but such a transition is not observed in liposomes containing
60 mol% cholesterol (Fig. 1). The polymorphic transition of cholesterol
monohydrate is not observed in any of the samples (data not shown).
Preparations of pure cholesterol (i.e., no DOTAP) also exhibited the
anhydrous cholesterol transition (data not shown). These data in-
dicate that anhydrous cholesterol is only formed at very high cho-
lesterol contents, and that cholesterol associated with DOTAP does not
exhibit a transition at this temperature.
Additional calorimetric studies were conducted to more precisely
determine the cholesterol content at which cholesterol molecules
coalesce into anhydrous cholesterol domains. Liposomes were pre-
paredwith increasing cholesterol contents ranging from60 to 70mol%
and analyzed by DSC. The results show that the anhydrous cholesterol
transition is not observed until cholesterol contents reach 66 mol%
(Fig. 2). Thus, we conclude from these results that cholesterol as-
sociates with DOTAP in a 2:1 mole ratio (cholesterol:DOTAP).
While the data above show that anhydrous cholesterol is present in
liposomes prepared at high cholesterol contents, we conducted similar
experimentswith lipid/DNAcomplexes (lipoplexes) to determine if the
anhydrous cholesterol transition would be inhibited by complexation
with DNA. The results in Fig. 3 clearly show that anhydrous cholesterol
is present in lipoplexes preparedwith liposomes composed of 70% and
80% cholesterol. As seen in the liposome samples (Fig. 1), the pre-
parations containing 80% cholesterol exhibited the largest enthalpy
change associated with the transition, indicating that more anhydrous
cholesterol is present at higher cholesterol contents. To further in-
vestigate the effect of DNA binding on cholesterol domains, additional
studies were performed to ascertain whether the relative amount of
DNA bound to the liposome (as reﬂected by the +/− charge ratio)
altered domain formation. As shown in Fig. 4, the transition enthalpy
calculated from the DSC scans remained constant in preparations
containing 70% or 80% cholesterol, regardless of charge ratio. Con-
sidering that DNA interactswith cationic liposomes via an electrostaticTable 1
Particle size and zeta potential of DOTAP/cholesterol lipoplex at charge ratio of 4:1
Cholesterol mol% Particle diameter (mm) Zeta potential (mV)
60 86.5±5.3 42.1±4.7
70 119.5±5.5 48.2±2.9
80 165.8±16.4 45.8±5.1
Data represent mean±one standard deviation of three replicates.interaction [23, 24], it would be expected that DNA would bind to the
DOTAP molecules instead of to an uncharged domain composed of
neutral cholesterol molecules.
3.2. Particle size and zeta potential measurement
Particle size and zeta potential of lipoplexes with 60, 70 and 80%
cholesterol were measured at charge ratio of 4:1 (Table 1). The size of
particles increases as cholesterol content rises from 60% to 80%,
ranging from 86.5 nm to 165 nm, consistent with the incorporation of
additional cholesterol molecules into the lipoplex particle. In contrast,
the zeta potential of lipoplexes does not show statistical difference
among samples with 60%, 70% and 80% cholesterol. It should be noted
that the zeta potential of lipoplexes in all formulations is above
+40 mV, which likely serves to offer some stability to the suspension
via electrostatic stabilization.
3.3. In vitro transfection
In the presence of 50% FBS medium, KB cells were transfected by
lipoplexes formulated with DOTAP/cholesterol at 60, 70 and 80 mol%
cholesterol. Transfection efﬁciencymeasured by luciferase expression is
shown in Fig. 5. As indicated by DSC, cholesterol domains form in
DOTAP/cholesterol lipoplexes at 70% and 80% cholesterol, but not at 60%
cholesterol. Our results demonstrate that transfection efﬁciency ismuch
higher in the formulations containing a cholesterol domain (70 and
80 mol%) as compared to that without the domain (60 mol%). Separate
experiments wherein cholesterol was prepared separately and physi-
cally mixed with DOTAP/cholesterol lipoplexes clearly showed that the
presence of cholesterol that is not associated with the lipoplex does notFig. 6. Size measurement of lipoplexes at charge ratio of 4:1 by dynamic light scattering.
Lipoplexes were prepared by mixing equal volumes of 0.5 mM DOTAP/cholesterol and
40 μg/ml plasmid DNA. Particle size of lipoplexes in buffer (closed bar) and after incubation
in serum (open bar) is shown as the mean+one standard deviation of three replicates.
Asterisks represent pb0.05 between two groups of samples by Student's t-test.
2180 L. Xu, T.J. Anchordoquy / Biochimica et Biophysica Acta 1778 (2008) 2177–2181enhance transfection (data not shown). These latter experiments
demonstrate that anhydrous cholesterol must be present within the
lipoplex (as opposed to free cholesterol crystallites) to provide the
enhanced transfection rates observed in Fig. 5.
3.4. Serum stability of lipoplexes
Previous studies have demonstrated that lipoplexes containing
80% cholesterol have a remarkable ability to resist aggregation in
serum [7]. We have conducted similar experiments in 50% FBS and
obtained results that are virtually identical to that reported by Zhang
and Anchordoquy [7] (data not shown). While turbidity measure-
ments are convenient for monitoring aggregation over time, it is
difﬁcult to translate a known change in turbidity to a deﬁned particle
size. In performing serum stability experiments, we determined that
accurate and reproducible particle sizes of lipoplexes incubated in
serum could be obtained upon dilution. Accordingly, particle sizes of
lipoplexes containing different cholesterol contents were monitored
before and after a 30-minute incubation in 50% FBS. The data in Fig. 6
demonstrate that lipoplexes possessing 80% cholesterol do not
aggregate under these conditions, unlike lower cholesterol contents.
However, although there is a signiﬁcant change in particle size for
lipoplexes containing 60% and 70% cholesterol, the resulting particle
size after a 30-minute incubation in 50% FBS is still smaller than that of
the non-aggregated lipoplexes possessing 80% cholesterol.
3.5. Serum protein binding
A ﬁnal set of experiments was conducted to determine the extent
to which serum albumin binds to lipoplexes possessing different
cholesterol contents. As shown in Fig. 7, lipoplexes containing very
low levels of cholesterol (i.e., 20 mol%) bind albumin very efﬁciently,
but protein binding is reduced at higher cholesterol contents.
Interestingly, there is no signiﬁcant difference in the amount of
protein bound to lipoplexes containing ≥60% cholesterol. This ﬁnding
suggests that the increased transfection observed for lipoplexes with
80% cholesterol (Fig. 5) cannot be explained by a change in the amount
of protein bound. Furthermore, since our data show that the amount
of protein bound per un-neutralized DOTAPmolecule is constant with
high cholesterol content (60, 70 and 80 mol%), we can conclude that
the association of additional cholesterol with the lipoplex does not
alter the total amount of protein bound. Considering that lipoplexes
possessing higher cholesterol contents are larger (Table 1), presum-
ably to accommodate the additional cholesterol, our data show that
serum albumin does not bind to the cholesterol domains. Since serum
proteins are thought to associate with lipoplexes via electrostatic
interactions [5], it would be expected that albumin would not bind to
an uncharged cholesterol domain.Fig. 7. Bovine serum albumin binding to lipoplexes with cholesterol content at 20, 40,
60, 70 and 80 mol%. Protein bound to lipoplexes was normalized to the amount of
DOTAP in each preparation that remains un-neutralized by DNA. The data represent the
mean+one standard deviation of three replicates. Asterisks represent pb0.05 when
compared to samples of 40% cholesterol by Student's t-test.4. Discussion
The present study shows that anhydrous cholesterol domains form
in DOTAP/cholesterol liposomes when formulated at 70 and 80 mol%
cholesterol. The polymorphic transition of anhydrous cholesterol is
detected at 38–40 °C on a DSC heating scan, however, no transition of
the dehydration of cholesterol monohydrate at 80 °C was detected
(data not shown). DSC experiments performed on a series of samples
containing cholesterol from 60–70 mol% in 1% increments show
that the critical level of cholesterol at which domains are formed is
approximately 66 mol% (Fig. 2). This is in agreement with an X-ray
diffraction study byHuang J et al. [19] inwhich themaximumsolubility
of cholesterol in a phosphatidylcholine bilayer was determined to be
66 mol%. In their case, the solubility limit of cholesterol was inter-
preted as the concentration of cholesterol at which some cholesterol
molecules are not effectively covered by phospholipid headgroups.
Considering that the acyl chains of the DOPC used in their study are
identical to that in DOTAP, the similar mixing behavior observed with
these two monounsaturated diacyl lipids is consistent with studies
suggesting that cholesterol solubility is predominantly determined by
hydrophobic interactions [25].
The area under the transition curve of DOTAP/80% cholesterol is
greater than that of the 70% formulation, which indicates more
cholesterol is in the domain. Taking into account that the transition of
anhydrous cholesterol has an enthalpy of 910 cal/mol [18], the amount
of cholesterol in the domain can be calculated. The mole fraction of
cholesterol in the domain is calculated to be 8.8,13.0, 20.4 and 23.3% in
67, 68, 70 and 80% cholesterol formulations, respectively. Interestingly,
the mole fraction of cholesterol that is associated with DOTAP (as
opposed to that in the domain) is virtually constant in these samples
(54.9±3.7%). The fact that this value is below the threshold level at
which anhydrous cholesterol is detected by DSC (Fig. 2) suggests that
supersaturation occurs prior to the formation of anhydrous choles-
terol domains.
Our results demonstrate that DNA binding to the DOTAP/cholesterol
liposomes does not disrupt domain formation (Fig. 3), and that the
relative amount of DNA bound to the liposome (as reﬂected by the +/−
charge ratio) also does not alter the amount of anhydrous cholesterol in
the lipid/DNA complex (Fig. 4). These results are not surprising if we
consider that DNA interacts with the liposome via electrostatic inter-
actions, and therefore uncharged cholesterol domains would not be
expected to associate with DNA. It must be recognized that the DOTAP/
cholesterol ratio, and thus the charge density, is constant outside the
cholesterol domain above 66 mol% cholesterol, therefore the number
of cholesterol molecules contributing to the domain represents a sig-
niﬁcant difference among formulations containing 60, 70 and 80%
cholesterol. In addition, particle size increases at higher cholesterol
contents, but all particles remained below 200 nm (Table 1).While all of
these particles are sufﬁciently small to effectively transfect cells, studies
have indicated that particles with smaller size would show higher
transfection efﬁciency [26]. Surprisingly, transfection is progressively
enhanced at higher cholesterol contents at which particle size is the
largest (Fig. 5). Furthermore, even though lipoplexes are known to
aggregate in serum [6], ourmeasurements indicate that the aggregation
observed with lipoplexes lacking domains (60% cholesterol) does not
result in particle sizes as large as that seen with the aggregation-
resistant lipoplex formulation (80% cholesterol; Fig. 6). These results
suggest that any reduction in transfection due to lower cell uptake of
the larger size lipoplexes containing 80% cholesterol is more than
compensated for by the presence of a cholesterol domain.
Another potential factor that can contribute to the higher trans-
fection rates observed with lipoplexes containing 80% cholesterol is
the interaction with negatively charged serum proteins, e.g., albumin
[4]. Considering that our transfection experiments were conducted
in 50% serum to better approximate conditions upon intravenous
administration, alterations in the amount of bound protein might be
2181L. Xu, T.J. Anchordoquy / Biochimica et Biophysica Acta 1778 (2008) 2177–2181expected to affect cell binding and uptake. Our data show that albumin
binding to lipoplexes is dramatically reduced by cholesterol contents
up to 40%, binding is comparable above this threshold cholesterol level
(Fig. 7). These results indicate that the increased transfection observed
at the highest cholesterol content cannot be explained by altered
protein binding, suggesting that the cholesterol domain may exert an
effect on intracellular processes associated with transfection.
In conclusion, our study shows that anhydrous cholesterol domains
are formed in liposomes and lipoplexes at cholesterol contents above
66mol%. The amount of cholesterol in the domain is not altered by the
amountofDNAbound (i.e., charge ratio), andwhile domain-containing
lipoplexes do possess greater resistance to serum-induced aggrega-
tion, this effect cannot be explained by reductions in the amount of
bound protein. Interestingly, the enhanced transfection rates observed
with lipoplexes containing a cholesterol domain cannot be explained
by the retention of smaller particle sizes in the presence of serum.
Although the mechanism responsible for the increased transfection is
unclear, we suggest that the lack of protein and DNA binding to the
uncharged cholesterol domain may contribute to this effect. It should
be noted that recent in vivo work has demonstrated the ability of
lipoplexes containing 80% cholesterol to preferentially accumulate in
tumors [27].
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